Romosozumab in postmenopausal women with low bone mineral density. - Wikidata - awgldk - TriplyDB

Romosozumab in postmenopausal women with low bone mineral density.

Romosozumab in postmenopausal women with low bone mineral density.

http://www.wikidata.org/entity/Q50481558

about

Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype Bone repair with skeletal stem cells: rationale, progress to date and clinical application Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Sclerostin Inhibition in the Management of Osteoporosis From disease to treatment: from rare skeletal disorders to treatments for osteoporosis New insights into treatment of osteoporosis in postmenopausal women Recent developments in osteogenesis imperfecta Emerging Therapies for Osteoporosis Male Osteoporosis in the Elderly Role of bone-anabolic agents in the treatment of breast cancer bone metastases Osteochemonecrosis: an overview Anorexia nervosa and bone metabolism Fracture healing: mechanisms and interventions Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density Antibodies to watch in 2015 Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Novel advances in the treatment of osteoporosis.Efficacy of Osteoporosis Therapies in Diabetic Patients.Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.Profile of romosozumab and its potential in the management of osteoporosis.Parathyroid hormone: anabolic and catabolic actions on the skeleton Wnt signaling and osteoporosis.Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma The best of both worlds - managing the cancer, saving the bone.Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots.Osteoclasts: more than 'bone eaters'.Novel therapeutic targets in myeloma bone disease.Aneuploidy and skeletal health.Inhibitors of sclerostin: emerging concepts.Osteoblasts as leukemia-initiating cells.Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels Romosozumab for the treatment of osteoporosis.Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation.

P2860

Q21284514-AD4BCD4D-012A-4D46-AD29-0E4540419239 Q26744340-A2320758-45E0-49FF-A444-F2962EB1AD22 Q26744599-82309B36-29C0-410B-95FF-39B087232341 Q26750713-26A86BD5-CF68-4B2C-979B-4BC227CCD81D Q26764854-6FBA69B4-178D-4DA0-B01B-3DB9AA49D940 Q26777910-3F46EBD8-8968-49BB-AD6C-CA339BC4A39E Q26781674-EC57E363-A254-484F-88D7-30FA698E4DDB Q26782109-92BD06C2-4737-4005-A8B9-E14D630F8B97 Q26784352-40F5479A-A9FB-4BB2-99C1-CFBF34F4EF7B Q26822732-645AF3F5-C5E0-41C8-A817-7B5CD83D01E9 Q26827072-8625859E-DE87-40BA-AFF3-3C53CFC959B7 Q26829507-65B69814-8D15-4A9B-A7F9-6D1DB3383216 Q26851958-5266ACA8-1084-42A5-8299-BBDEA3ED00FF Q27022580-A8296788-32DE-4853-9E98-6E2AD2B4CCE1 Q28072340-C07CA955-89FC-4A11-8DCA-D127C597B404 Q28078585-02793DF0-9CC7-49AF-A82E-D4BB7E6307F8 Q28247445-EC151702-F308-4770-B5DE-4E52383E78DE Q28253501-50DC9DA3-11B2-4657-83BA-0E5270430ADD Q30234751-A66B79DD-6EBB-4565-9F17-01ECDF2D8D32 Q30248319-E274B4A1-AB9F-4C05-955B-8A0538FE7A61 Q30248776-0F3BAF4D-5CAD-4A5C-AA8B-E9908C6ABDD8 Q30713102-3BCDF501-CB7D-43D3-BFA4-CB77380B9437 Q31038073-859F7C67-C0A9-4316-95F9-8524EE8BE6A0 Q33554916-20BF36D1-F45E-4F60-B784-8583F03D250C Q33596475-9BBAE311-0FC2-4568-AAB9-94F3D69D12FF Q33609126-0CA7C1DD-E73D-4452-939E-7B4BF8D02AE8 Q33784662-DC8AFBCF-9EA4-4AF8-A5FA-014CFDEA97DA Q33812106-BF597ED1-FB3B-478C-BADE-3AE28EF02F21 Q33835734-F588E956-F639-4A6B-887B-6A98FD71A7EE Q33856318-3EEA7369-737A-4A94-B305-659AAD35416A Q33920055-194BD238-23A0-48F2-8DE2-39C12539B3E2 Q33925973-0C1DC909-0419-4001-B9FE-F6BA8B264858 Q33993757-E04A8CC4-11CE-46D7-9081-7A03F8D0AB78 Q34025065-95EC8A7F-96D0-46B3-9A52-A65D4D60B102 Q34059928-89C4C5B1-6E8C-4EE7-A0FA-DF5E4921DF69 Q34069470-C8D903E3-03E4-4B7D-AF2A-A87AA922A7FF Q34171839-5E15B3E0-E605-4F37-AF43-E3A4EDCD38D1 Q34661015-B8A99B11-975E-4844-AF52-23EFA7D7F50D Q34680463-72DDE465-73BD-40C9-80D8-5A687DDCCF59 Q34709060-AC027365-ADF2-44D7-B9F6-F882AC277CE5

P2860

Romosozumab in postmenopausal women with low bone mineral density.

http://www.wikidata.org/entity/Q50481558

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Romosozumab in postmenopausal women with low bone mineral density.

@en

Romosozumab in postmenopausal women with low bone mineral density.

@nl

type

label

Romosozumab in postmenopausal women with low bone mineral density.

@en

Romosozumab in postmenopausal women with low bone mineral density.

@nl

prefLabel

Romosozumab in postmenopausal women with low bone mineral density.

@en

Romosozumab in postmenopausal women with low bone mineral density.

@nl

P1433

Q50481558-85EE170E-784B-4AAB-9092-42B2251A31D6

P1476

Q50481558-02F1DB31-8D6E-474C-A620-91B018D51179

P2093

Q50481558-0D1CC9E7-82DF-4941-A416-BE68DF7ED6B4

Q50481558-3F608DC2-5629-49FE-9A30-408685939E42

Q50481558-50480AC8-86E3-40FD-8ED2-EAF062586DEB

Q50481558-50A65A25-7001-4978-BBB4-492FD67B39A0

Q50481558-A9B51D27-AFD3-48C1-A022-72A2B9D7A228

Q50481558-AA988075-E4E6-4AE7-8A11-2C88BD36EF8F

Q50481558-ACF845AD-A737-438C-BF55-054A063EAFF8

Q50481558-B67CCB7A-7B14-4A9C-9BD6-1054C27210B8

Q50481558-BDAFEF04-5999-43CE-81E4-CEC4BC988D9D

Q50481558-C31191E6-2C38-49B1-8099-2EB25101A381

P304

Q50481558-12EA8A0E-BFBB-4FF6-A7D8-6AC3AED8D533

P31

Q50481558-2AFBF367-8AB4-4E15-A038-D180B5A6709D

P356

Q50481558-191B3C88-3A29-40D3-8440-1F8EE83C0DB8

P407

Q50481558-75F36955-8045-4D55-AB51-775DA0EE93B2

P433

Q50481558-E3439015-7C34-4BB3-A01E-850F3B26609E

P478

Q50481558-8A8A81C5-2E12-4EDE-8BE0-382ADD6B85F0

P50

Q50481558-4730872F-645B-4CAD-AA56-62B6920A3F1A

Q50481558-CBD29A83-3C69-4812-9208-221135995DE0

Q50481558-D2665418-BBDA-427D-8626-554F755F1BDF

P577

Q50481558-21B786F5-734F-4CF0-B025-5C0AF195004A

P5875

Q50481558-CF65216C-57A7-4761-B0BD-5F86E150BDBE

P698

Q50481558-1F55F08B-1B90-4FCC-90F0-92B0FC65DD8F

P356

P1433

The New England Journal of Medicine

P1476

Romosozumab in postmenopausal women with low bone mineral density

@en

P2093

Andreas Grauer

http://www.w3.org/2001/XMLSchema#string

Bente L Langdahl

http://www.w3.org/2001/XMLSchema#string

Cesar Libanati

http://www.w3.org/2001/XMLSchema#string

Henry G Bone

http://www.w3.org/2001/XMLSchema#string

Jean-Yves Reginster

http://www.w3.org/2001/XMLSchema#string

Jose R Zanchetta

http://www.w3.org/2001/XMLSchema#string

Judy Maddox

http://www.w3.org/2001/XMLSchema#string

Leonid Katz

http://www.w3.org/2001/XMLSchema#string

Michael A Bolognese

http://www.w3.org/2001/XMLSchema#string

Scott M Wasserman

http://www.w3.org/2001/XMLSchema#string

P304

412-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1305224

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Michael R McClung

Jacques P. Brown

Adolfo Díez-Pérez

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259559381

http://www.w3.org/2001/XMLSchema#string

P698

24382002

http://www.w3.org/2001/XMLSchema#string